Market Overview
The European insulin delivery devices market covers a range of products designed to help patients with diabetes administer insulin safely and effectively, including insulin pens, pen needles, insulin pumps, and smart connected devices. In 2025, the Europe-specific insulin delivery devices segment is estimated at approximately USD 2.88 billion, with projections to reach USD 3.17 billion by 2030. This sits within the broader European drug delivery devices market, which reached an estimated USD 381 million in 2025, and represents a portion of the global insulin delivery landscape valued at roughly USD 19.3 billion in 2025.
- •Europe Insulin Delivery Devices Market estimated at USD 2.88 billion in 2025, projected to reach USD 3.17 billion by 2030
- •Europe Drug Delivery Devices Market valued at approximately USD 381 million in 2025
- •Global insulin delivery devices market valued at USD 19.3 billion in 2025
Growth Drivers
Rising diabetes prevalence across Europe, combined with aging demographics in Spain and other EU nations, continues to expand the patient population requiring insulin therapy. Advances in connected health technology, particularly smart insulin pens, are driving device adoption, with the Europe Smart Insulin Pens market growing from roughly USD 109 million in 2024 toward USD 223 million by 2030. Favorable reimbursement policies in national healthcare systems and the shift toward home-based care models further support market expansion.
- •Rising diabetes prevalence and aging populations across EU member states
- •Smart insulin pens segment projected to grow from USD 109 million in 2024 to USD 223 million by 2030
- •Advancing connected health technology and home-based care adoption
Segmentation and Regional Analysis
The market is segmented by product type, including traditional insulin pens, pen needles, insulin pumps, and emerging smart insulin pens with dose-tracking and connectivity features. Geographically, Western Europe including Spain, Germany, France, and the UK represents the largest share of the European market, supported by advanced healthcare infrastructure and higher diabetes diagnosis rates. The smart insulin pens sub-segment is showing the strongest growth trajectory within the region.
- •Product categories: insulin pens, pen needles, pumps, and connected smart pens
- •Western Europe leads regional market share, with Spain as a significant national market
- •Smart insulin pens represent the fastest-growing device sub-segment in Europe
Trends and Outlook
What are the recent trends and outlook?
The market is moving toward digitization with connected insulin pens that integrate with mobile apps and glucose monitoring systems to improve patient adherence and data tracking. Miniaturization of pumps and the development of closed-loop delivery systems represent longer-term innovation frontiers. Regulatory emphasis on patient safety and data privacy under EU medical device regulations continues to shape product development and market entry timelines across the region.
- •Connected and smart insulin pens with digital adherence features are gaining adoption across Europe
- •Integrated care platforms combining insulin delivery with glucose monitoring are emerging
- •EU medical device regulations and reimbursement policies shape market access and innovation timelines
Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.
Connect to an analyst →Market size and forecast are Claight Analysis, informed by public research and industry data. Historical years before 2025 and all forecast years are Claight estimates at the stated CAGR. Retrieved 2026.